MiniMed (Nasdaq: MMED) is celebrating its first day as an independent diabetes tech company, with the full completion of its spinoff from the Medtronic mothership.
This week Medtronic reported the final results of its exchange offer for MiniMed stock, where it divested all of its remaining equity stake in the company through the swapping of more than 252.8 million shares.
“We are grateful to Medtronic for its partnership and support in reaching this point. As an independent company, we have the freedom to make the decisions we believe are right for our business and the people we serve, and the responsibility to see those decisions through,” MiniMed CEO Que Dallara said in a statement. “Our focus now is to put that independence to work and continue advancing what is possible in diabetes care.”
Read the full story at our sister site, Drug Delivery Business News
